CDKN2A and breast carcinoma: The correlations between mutational status and response to CDK4/6 inhibition are also clear in breast cancer, where downregulation of CDKN2A and amplification of CDK4 or CDK6 were correlated with sensitivity to CDK4/6 inhibition [7].